NCT02231879View on ClinicalTrials.gov

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

October 8, 2020

Study Completion Date

February 24, 2021

Conditions
MyelokathexisInfectionsNeutropeniaWartsHypogammaglobulinemia
Interventions
DRUG

Plerixafor

Twice daily low dose injection for 14 months.

DRUG

G-CSF

Twice daily low dose injection for 14 months.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome | Biotech Hunter | Biotech Hunter